Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0

作者：

Linton, Kim M. ^{[1
,2
]}

Wahlin, Bjorn ^{[3
,4
]}

Leppa, Sirpa ^{[5
]}

Morschhauser, Franck ^{[6
]}

Elliott, Brian ^{[7
]}

Liu, Tracy ^{[7
]}

Stirner, Mariana Cota ^{[8
]}

Abbas, Aqeel ^{[7
]}

Falchi, Lorenzo ^{[9
]}

机构：

[1] Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Manchester Canc Res Ctr, Manchester, Lancs, England

[3] Karolinska Inst, Stockholm, Sweden

[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[5] Univ Helsinki, Helsinki, Finland

[6] Univ Lille, CHU Lille, Lille, France

[7] Genmab, Princeton, NJ USA

[8] AbbVie, N Chicago, IL 60064 USA

[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH22-PO53

引用

页码：94 / 94

页数：1

共 50 条

[21] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003) [J].

Strati, Paolo ;

Agajanian, Richy ;

Lossos, Izidore S. ;

Coleman, Morton ;

Kridel, Robert ;

Wood, Andrew ;

Lesley, Robin ;

Wun, Chuan-Chuan ;

Stephens, Deborah M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) :887-898

[22] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up [J].

Salles, Gilles ;

Park, Steven I. ;

Phillips, Tycel J. ;

Amengual, Jennifer E. ;

Andorsky, David J. ;

Campbell, Philip ;

McKay, Pamela ;

Leonard, John P. ;

Chen, Yingxue ;

Chen, Jade ;

Bannerji, Rajat ;

Kapopara, Apoorva ;

Szanto, Attila ;

Morschhauser, Franck .

BLOOD, 2023, 142

[23] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL [J].

Ujjani, Chaitra S. ;

Wang, Hongkun ;

Skarbnik, Alan P. ;

Trivedi, Neel ;

Ramzi, Pari ;

Khan, Nadia ;

Cheson, Bruce D. .

BLOOD, 2017, 130

[24] Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study [J].

Craig, Michael ;

Hanna, Wahid T. ;

Cabanillas, Fernando ;

Chen, Chien-Shing ;

Parasuraman, Sudha ;

Neuwirth, Rachel ;

O'Connor, Owen A. .

BLOOD, 2010, 116 (21) :1153-1154

[25] Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial [J].

Izutsu, Koji ;

Akahane, Daigo ;

Toubai, Tomomi ;

Saito, Toko ;

Mishima, Yuko ;

Fujisaki, Tomoaki ;

Nishikori, Momoko ;

Kumode, Takahiro ;

Suehiro, Youko ;

Ishitsuka, Kenji ;

Conlon, Rebekah ;

Takahashi, Ami ;

Mansson, Barbara D'Angelo ;

Favaro, Elena ;

Fukuhara, Noriko .

LEUKEMIA & LYMPHOMA, 2025,

[26] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. [J].

Batlevi, Connie Lee ;

Park, Steven I. ;

Phillips, Tycel Jovelle ;

Amengual, Jennifer ;

Andorsky, David Jacob ;

Campbell, Philip ;

Mckay, Pamela ;

Leonard, John Paul ;

Sondhi, Manu ;

Yang, Jay ;

Chen, Yingxue ;

O'Connor, Heather ;

Slatcher, Pamela ;

Morschhauser, Franck .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[27] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma. [J].

Sehn, Laurie Helen ;

Hubel, Kai ;

Luminari, Stefano ;

Salar, Antonio ;

Wahlin, Bjorn E. ;

Gopal, Ajay K. ;

Bonnet, Christophe Marc ;

Paneesha, Shankara ;

Trneny, Marek ;

Mashegu, Hafsat Umar ;

Lihou, Christine Francis ;

Li, Di ;

Scholz, Christian W. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[28] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial [J].

M Wang ;

N Fowler ;

N Wagner-Bartak ;

L Feng ;

J Romaguera ;

S S Neelapu ;

F Hagemeister ;

M Fanale ;

Y Oki ;

B Pro ;

J Shah ;

S Thomas ;

A Younes ;

C Hosing ;

L Zhang ;

K J Newberry ;

M Desai ;

N Cheng ;

M Badillo ;

M Bejarano ;

Y Chen ;

K H Young ;

R Champlin ;

L Kwak ;

L Fayad .

Leukemia, 2013, 27 :1902-1909

[29] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial [J].

Wang, M. ;

Fowler, N. ;

Wagner-Bartak, N. ;

Feng, L. ;

Romaguera, J. ;

Neelapu, S. S. ;

Hagemeister, F. ;

Fanale, M. ;

Oki, Y. ;

Pro, B. ;

Shah, J. ;

Thomas, S. ;

Younes, A. ;

Hosing, C. ;

Zhang, L. ;

Newberry, K. J. ;

Desai, M. ;

Cheng, N. ;

Badillo, M. ;

Bejarano, M. ;

Chen, Y. ;

Young, K. H. ;

Champlin, R. ;

Kwak, L. ;

Fayad, L. .

LEUKEMIA, 2013, 27 (09) :1902-1909

[30] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma [J].

Patel, Krish ;

Bailey, Neil ;

Pagel, John M. .

BLOOD, 2020, 136

← 1 2 3 4 5 →